Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
Renaud Felten, Floriane Gallais, Cédric Schleiss, Emmanuel Chatelus, Rose-Marie Javier, Luc Pijnenburg, Christelle Sordet, Jean Sibilia, Laurent Arnaud, Samira Fafi-Kremer, Jacques-Eric Gottenberg
Topics & Concepts
MedicineDiscontinuationRheumatoid arthritisImmunologyHumoral immunityRituximabVaccinationAntibodyCellular immunityImmune systemImmunityImmunopathologyImmunogenicityAdjuvantDiseaseInternal medicineClinical diseaseAntibody therapyArthritisAutoimmune diseaseAntibody responseClinical trialSARS-CoV-2 and COVID-19 ResearchImmunotherapy and Immune ResponsesCAR-T cell therapy research